CTOs on the Move

Nanoscope Therapeutics

www.nanostherapeutics.com

 
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Care Angel

Care Angel is the industry leader in automation and exponentially scalable solutions for continuous engagement, management, surveillance, triage, navigation and care of millions. ANGEL, the world`s first voice-enabled, AI-Nurse Assistant comes to life through the company`s award-winning SmartCare Platform. ANGEL enables the most effective, efficient and scalable way to engage, monitor and manage large, at-risk populations with complex and chronic conditions at the lowest cost, starting with a simple phone call or text-based care conversation. Care Angel`s AI solutions give care teams the ability to conversationally collect accurate patient data, consistently and continuously, receiving regular updates on vitals and well-being to inform and manage real-time interventions and avoid missed care opportunities.

SciMar

SciMar is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caloptima Health Partnership

Caloptima Health Partnership is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.

Optivus

Optivus is a San Bernardino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.